Citations

Clear

6 citation(s) found for "Keller, Norma".

Critical Care Cardiology Trials Network (CCCTN): a cohort profile
Metkus, Thomas S. , Baird-Zars, Vivian M., Alfonso, Carlos E., Alviar, Carlos L. , Barsness, Gregory W. , Bertić, Mia , Bohula, Erin A. , Burke, James A. , Burstein, Barry , Cooper, Howard A., Daniels, Lori B. , Goldfarb, Michael , Katz, Jason N. , Keeley, Ellen C. , Keller, Norma, Kenigsberg, Benjamin B. , Kontos, Michael C. , Lawler, Patrick R. , Leibner, Evan , Menon, Venu , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Papolos, Alexander , Pierce, Matthew J, Prasad, Rajnish, Pisani, Barbara , Smith, Timothy D., Snell, R. Jeffrey, So, Derek , Ternus, Bradley , Teuteberg, Jeffrey J. , Zakaria, Sammy , Goldfarb, Michael , Pierce, Matthew , Fordyce, Christopher B , Goldfarb, Michael , Solomon, Michael A , van Diepen, Sean , Goldfarb, Michael , Lawler, Patrick , Daniels, Lori B , Bohula, Erin A , Zakaria, Sammy , O'Brien, Connor G , Pierce, Matthew J , Barnett, Christopher F. , Berg, David D. , Burke, James, Chaudhry, Sunit‐Preet , Fordyce, Christopher B. , Ghafghazi, Shahab , Kwon, Younghoon, Liu, Shuangbo , Prasad, Rajnish, Potter, Brian J , Roswell, Robert O. , Sinha, Shashank S , Shah, Kevin S , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | August 27, 2022 | Volume: 8 | Issue: 7 | Pages: 703-708

10.1093/ehjqcco/qcac055 | PMID 36029517 Get It

AbstractAimsThe aims of the Critical Care Cardiology Trials Network (CCCTN) are to develop a registry to investigate the epidemiology of cardiac critical illness and to establish a multicentre research network to conduct randomised clinical trials (RCTs) in patients with cardiac critical illness.Methods and resultsThe CCCTN was founded in 2017 with 16 centres and has grown to a research network of over 40 academic and clinical centres in the United States and Canada. Each centre enters data for consecutive cardiac intensive care unit (CICU) admissions for at least 2 months of each calendar year. More than 20 000 unique CICU admissions are now included in the CCCTN Registry. To date, scientific observations from the CCCTN Registry include description of variations in care, the epidemiology and outcomes of all CICU patients, as well as subsets of patients with specific disease states, such as shock, heart failure, renal dysfunction, and respiratory failure. The CCCTN has also characterised utilization patterns, including use of mechanical circulatory support in response to changes in the heart transplantation allocation system, and the use and impact of multidisciplinary shock teams. Over years of multicentre collaboration, the CCCTN has established a robust research network to facilitate multicentre registry-based randomised trials in patients with cardiac critical illness.ConclusionThe CCCTN is a large, prospective registry dedicated to describing processes-of-care and expanding clinical knowledge in cardiac critical illness. The CCCTN will serve as an investigational platform from which to conduct randomised controlled trials in this important patient population.
Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry
Berg, David D. , Barnett, Christopher F. , Kenigsberg, Benjamin B. , Papolos, Alexander , Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bohula, Erin A. , Brennan, Joseph , Burke, James A. , Cremer, Paul , Daniels, Lori B. , DeFilippis, Andrew P. , Granger, Christopher B. , Hollenberg, Steven M. , Horowitz, James M. , Gladden, James D., Katz, Jason N. , Keeley, Ellen C. , Keller, Norma , Kontos, Michael C. , Lawler, Patrick R. , Menon, Venu , Metkus, Thomas S. , Miller, P. Elliott , Nativi-Nicolau, José , Newby, L. Kristin , Park, Jeong-Gun, Phreaner, Nicholas , Roswell, Robert O. , Schulman, Steven P. , Snell, R. Jeffrey, Solomon, Michael A. , Teuteberg, Jeffrey J. , Tymchak, Wayne , Morrow, David A. , Lawler, Patrick , Solomon, Michael A , Morrow, David A , Granger, Christopher B , Roswell, Robert O , Daniels, Lori B , Bohula, Erin A , Cremer, Paul C , Berg, David , Burke, James A., Carnicelli, Anthony , Chaudhry, Sunit‐Preet , Gerber, Daniel , Park, Jeong‐Gun , Sinha, Shashank S , Diepen, Sean van

Mayo Clinic

Circulation: Heart Failure | November 11, 2019 | Volume: 12 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.119.006635 | PMID 31707801 Get It

Background: Temporary mechanical circulatory support (MCS) devices provide hemodynamic assistance for shock refractory to pharmacological treatment. Most registries have focused on single devices or specific etiologies of shock, limiting data regarding overall practice patterns with temporary MCS in cardiac intensive care units. Methods: The CCCTN (Critical Care Cardiology Trials Network) is a multicenter network of tertiary CICUs in North America. Between September 2017 and September 2018, each center (n=16) contributed a 2-month snapshot of consecutive medical CICU admissions. Results: Of the 270 admissions using temporary MCS, 33% had acute myocardial infarction-related cardiogenic shock (CS), 31% had CS not related to acute myocardial infarction, 11% had mixed shock, and 22% had an indication other than shock. Among all 585 admissions with CS or mixed shock, 34% used temporary MCS during the CICU stay with substantial variation between centers (range: 17%–50%). The most common temporary MCS devices were intraaortic balloon pumps (72%), Impella (17%), and veno-arterial extracorporeal membrane oxygenation (11%), although intraaortic balloon pump use also varied between centers (range: 40%–100%). Patients managed with intraaortic balloon pump versus other forms of MCS (advanced MCS) had lower Sequential Organ Failure Assessment scores and less severe metabolic derangements. Illness severity was similar at high- versus low-MCS utilizing centers and at centers with more advanced MCS use. Conclusions: There is wide variation in the use of temporary MCS among patients with shock in tertiary CICUs. While hospital-level variation in temporary MCS device selection is not explained by differences in illness severity, patient-level variation appears to be related, at least in part, to illness severity.
Epidemiology of Shock in Contemporary Cardiac Intensive Care Units
Berg, David D. , Bohula, Erin A. , Katz, Jason N. , Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Burke, James A. , Cremer, Paul , Cruz, Jennifer , Daniels, Lori B. , DeFilippis, Andrew P. , Haleem, Affan , Hollenberg, Steven M. , Horowitz, James M. , Keller, Norma, Kontos, Michael C. , Lawler, Patrick R. , Menon, Venu , Metkus, Thomas S. , Ng, Jason, Orgel, Ryan, Overgaard, Christopher B., Park, Jeong-Gun, Phreaner, Nicholas , Roswell, Robert O. , Schulman, Steven P. , Snell, R. Jeffrey, Solomon, Michael A. , Ternus, Bradley , Tymchak, Wayne , Vikram, Fnu, Morrow, David A. , Lawler, Patrick , Solomon, Michael A , Morrow, David A , Roswell, Robert O , Daniels, Lori B , Bohula, Erin A , Cremer, Paul C , Berg, David , Diepen, Sean van , Barnett, Christopher F. , Burke, James A., Park, Jeong‐Gun

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 16, 2019 | Volume: 12 | Issue: 3 | Pages: No page available

10.1161/circoutcomes.119.005618 | PMID 30879324 Get It

Background Clinical investigations of shock in cardiac intensive care units (CICUs) have primarily focused on acute myocardial infarction (AMI) complicated by cardiogenic shock (AMICS). Few studies have evaluated the full spectrum of shock in contemporary CICUs. Methods and Results The Critical Care Cardiology Trials Network is a multicenter network of advanced CICUs in North America. Anytime between September 2017 and September 2018, each center (n=16) contributed a 2-month snap-shot of all consecutive medical admissions to the CICU. Data were submitted to the central coordinating center (TIMI Study Group, Boston, MA). Shock was defined as sustained systolic blood pressure <90 mm Hg with end-organ dysfunction ascribed to the hypotension. Shock type was classified by site investigators as cardiogenic, distributive, hypovolemic, or mixed. Among 3049 CICU admissions, 677 (22%) met clinical criteria for shock. Shock type was varied, with 66% assessed as cardiogenic shock (CS), 7% as distributive, 3% as hypovolemic, 20% as mixed, and 4% as unknown. Among patients with CS (n=450), 30% had AMICS, 18% had ischemic cardiomyopathy without AMI, 28% had nonischemic cardiomyopathy, and 17% had a cardiac cause other than primary myocardial dysfunction. Patients with mixed shock had cardiovascular comorbidities similar to patients with CS. The median CICU stay was 4.0 days (interquartile range [IQR], 2.5–8.1 days) for AMICS, 4.3 days (IQR, 2.1–8.5 days) for CS not related to AMI, and 5.8 days (IQR, 2.9–10.0 days) for mixed shock versus 1.9 days (IQR, 1.0–3.6) for patients without shock ( P <0.01 for each). Median Sequential Organ Failure Assessment scores were higher in patients with mixed shock (10; IQR, 6–13) versus AMICS (8; IQR, 5–11) or CS without AMI (7; IQR, 5–11; each P <0.01). In-hospital mortality rates were 36% (95% CI, 28%–45%), 31% (95% CI, 26%–36%), and 39% (95% CI, 31%–48%) in AMICS, CS without AMI, and mixed shock, respectively. Conclusions The epidemiology of shock in contemporary advanced CICUs is varied, and AMICS now represents less than one-third of all CS. Despite advanced therapies, mortality in CS and mixed shock remains high. Investigation of management strategies and new therapies to treat shock in the CICU should take this epidemiology into account.
Long-Term Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry
Feit, Frederick, Keller, Norma , Rosen, Allan D., Krone, Ronald J. , Berger, Peter B. , Shemin, Richard J., Williams, David O., Frye, Robert L. , Detre, Katherine M., Brooks, Maria M. , Sopko, George S. , Attubato, Michael

Mayo Clinic

Circulation | June 12, 2012 | Volume: 101 | Issue: 24 | Pages: 2795-2802

10.1161/01.cir.101.24.2795 | PMID 10859284 Get It

Background —The Bypass Angioplasty Revascularization Investigation (BARI) included 4039 patients with multivessel coronary artery disease; 1829 consented to randomization, and 2010 did not but were followed up in a registry. Thus, we can evaluate the outcome of physician-guided versus random assignment of percutaneous transluminal coronary angioplasty (PTCA) versus coronary artery bypass graft surgery (CABG). Methods and Results —We compared the baseline features and outcomes for PTCA and CABG in the overall registry and its predesignated subgroups. We assessed the impact of treatment by choice versus random assignment by comparing the results in the registry with those of the randomized trial. Statistical adjustments for differences in baseline characteristics were made. Within the registry, nearly twice as many patients were selected for PTCA (1189) as CABG (625); mortality at 7 years was similar for PTCA (13.9%) and CABG (14.2%) ( P =0.66) before and after adjustment for baseline differences between patients selected for PTCA versus CABG (adjusted RR, 1.02; P =0.86). In contrast to the randomized trial, the 7-year mortality rate of treated diabetics in the registry was equally high (26%) with PTCA or CABG. Seven-year mortality was higher for patients undergoing PTCA in the randomized trial than in the registry (19.1% versus 13.9%, P <0.01) but not for those undergoing CABG (15.6% versus 14.2%, P =0.57). The adjusted relative mortality risk for PTCA in the randomized versus registry population was 1.17 ( P =0.16). Conclusions —BARI physicians were able to select PTCA rather than CABG for 65% of registry patients who underwent revascularization without compromising long-term survival either in the overall population or in treated diabetics.
Increased Incidence of Periprocedural Complications Among Patients With Peripheral Vascular Disease Undergoing Myocardial Revascularization in the Bypass Angioplasty Revascularization Investigation
Rihal, Charanjit S. , Sutton‐Tyrrell, Kim, Guo, Ping , Keller, Norma , Jandová, R, Sellers, Mary Ann, Schaff, Hartzell V. , Holmes, David R. , Rihal, Charanjit S. , Schaff, Hartzell

Mayo Clinic

Circulation | June 11, 2012 | Volume: 100 | Issue: 2 | Pages: 171-177

10.1161/01.cir.100.2.171 | PMID 10402447 Get It

Background —Risks of coronary artery bypass graft surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) may be different in the presence of peripheral vascular disease (PVD). Methods and Results —We analyzed outcomes of 550 patients with PVD enrolled in the Bypass Angioplasty Revascularization Investigation randomized trial and registry. Compared with 1770 patients without PVD, those with PVD were older and had a greater prevalence of medical comorbid conditions. No significant differences in coronary anatomy or PTCA success rates were found. The risk of any major complication (death, myocardial infarction, stroke, coma, or emergency revascularization) after PTCA was significantly higher among patients with PVD (11.7% versus 7.8%, P =0.027). In multivariate analysis, this represented a 50% increase in the odds of having any major complication (multivariate odds ratio, 1.5; P =0.032). Among patients undergoing CABG, the risk of major complications was found to be markedly higher for patients with PVD (12%) than those without (6.1%, P =0.003) even after controlling for baseline differences (multivariate odds ratio, 1.8; P =0.018). Major differences between the PTCA and CABG groups were related primarily to a higher risk of neurological complications in PVD patients who had CABG (multivariate odds ratio, 2.8; P <0.001). Conclusions —We conclude that patients with PVD are at high risk for periprocedural complications after myocardial revascularization, in particular neurological events.